Skip to main content

Transcatheter Aortic Valve Replacement With the LOTUS Edge System: Early European Experience.

JACC. Cardiovascular interventions

Authors: Xavier Armario, Liesbeth Rosseel, Rajesh Kharbanda, Saib Khogali, Mohamed Abdel-Wahab, Nicolas M Van Mieghem, Didier Tchétché, Nicolas Dumonteil, Ole De Backer, James Cotton, Brian McGrath, Deepu Balakrishnan, Noman Ali, Serdar Farhan, Jubin Joseph, Gaetan Charbonnier, Taishi Okuno, Fiachra McHugh, David Hildick-Smith, Nicole Gilgen, Thijmen Hokken, Mark S Spence, Christian Frerker, Marco Angelillis, Marek Grygier, James Cockburn, Henrik Bjursten, Raban V Jeger, Rui Teles, Anna S Petronio, Thomas Pilgrim, Jan-Malte Sinning, Georg Nickenig, Lars Søndergaard, Daniel J Blackman, Darren Mylotte

OBJECTIVES: The aim of this study was to evaluate the short-term safety and efficacy of transcatheter aortic valve replacement (TAVR) with the LOTUS Edge system.

BACKGROUND: The LOTUS Edge system was commercially re-released in April 2019. The authors report the first European experience with this device.

METHODS: A multicenter, single-arm, retrospective registry was initiated to evaluate short-term clinical outcomes. Included cases are the first experience with this device and new implantation technique in Europe. Clinical, echocardiographic, and computed tomographic data were analyzed. Endpoints were defined according to Valve Academic Research Consortium-2 and were site reported.

RESULTS: Between April and November 2019, 286 consecutive patients undergoing TAVR with the LOTUS Edge system at 18 European centers were included. The mean age and Society of Thoracic Surgeons score were 81.2 ± 6.9 years and 5.2 ± 5.4%, respectively. Nearly one-half of all patients (47.9%) were considered to have complex anatomy. Thirty-day major adverse events included death (2.4% [n = 7]) and stroke (3.5% [n = 10]). After TAVR, the mean aortic valve area was 1.9 ± 0.9 cm, and the mean transvalvular gradient was 11.9 ± 5.7 mm Hg. None or trace paravalvular leak (PVL) occurred in 84.4% and moderate PVL in 2.0%. There were no cases of severe PVL. New permanent pacemaker (PPM) implantation was required in 25.9% among all patients and 30.8% among PPM-naive patients.

CONCLUSIONS: Early experience with the LOTUS Edge system demonstrated satisfactory short-term safety and efficacy, favorable hemodynamic data, and very low rates of PVL in an anatomically complex cohort. New PPM implantation remained high. Further study will evaluate if increasing operator experience with the device and new implantation technique can reduce the incidence of PPM implantation.

Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PMID: 33478633

Participating cluster members